Growth Hormone Deficiency (GHD)Symptoms, Doctors, Treatments, Advances & More
Learn About Growth Hormone Deficiency (GHD)
View Main Condition: Short Stature (Growth Disorders)
M Health Fairview Explorer Pediatric Specialty Clinic
Bradley Miller is a Pediatric Endocrinologist practicing medicine in Minneapolis, Minnesota. Dr. Miller is rated as an Elite provider by MediFind in the treatment of Growth Hormone Deficiency (GHD). He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Growth Hormone Deficiency (GHD), Pediatric Growth Hormone Deficiency, Short Stature (Growth Disorders), Adrenal Insufficiency Pediatric, and Hormone Replacement Therapy (HRT). Dr. Miller is board certified in Pediatric Endocrinology: American Board Of Pediatrics, 2003.
Winthrop Faculty Medical Affiliates University Faculty Practice Corpor
Paul Saenger is a Pediatrics provider practicing medicine in Mineola, New York. Dr. Saenger is rated as an Elite provider by MediFind in the treatment of Growth Hormone Deficiency (GHD). He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Pediatric Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Short Stature (Growth Disorders), and Idiopathic Short Stature (ISS).
Office
Roberto Salvatori is an Endocrinologist practicing medicine in Baltimore, Maryland. Dr. Salvatori is rated as an Elite provider by MediFind in the treatment of Growth Hormone Deficiency (GHD). He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Growth Hormone Deficiency (GHD), Hypopituitarism, Pituitary Tumor, Cushing's syndrome, and Hormone Replacement Therapy (HRT).
Summary: The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
Summary: This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children. It aims to determine whether the annual height velocity (an index of height growth rate) in children diagnosed with GHD after 52 weeks of GB06 intervention is comparable to that of Norditro...
Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center